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Background: Platinum-based chemotherapy (CT) for previously 
untreated advanced NSCLC improves survival (OS) and QoL but can 
have considerable toxicity. Erlotinib (E) (Tarceva®), an oral EGFR 
inhibitor, improves OS and progression-free survival (PFS) in 2nd- and 
3rd-line treatment of NSCLC with acceptable toxicity, similar response 
and OS to chemotherapy, and a suggestion that pts whose tumors 
express EGFR might beneﬁt most. In unselected CT-naïve NSCLC pts, 
adding daily E to concurrent CT did not improve outcome. Preclinical 
data suggest that intercalating E with CT may be superior to continu-
ous concurrent dosing. This trial was designed to evaluate E alone or 
E intercalated with CT for front-line treatment in an EGFR-selected 
population.
Methods: CT-naïve stage IIIB/IV NSCLC pts, ECOG PS 0-2, with 
EGFR-positive tumors by FISH or IHC were randomized equally to E 
150 mg/d or carboplatin AUC 6/paclitaxel 200 mg/m2 on Day 1 plus E 
150 mg/d on Days 2-15 of every 21-day cycle (ECP). After 4 cycles, pts 
in both arms continued daily E until PD, refusal, unacceptable toxicity, 
or death. EGFR IHC and FISH testing are performed at the University 
of Colorado Cancer Center with a planned 5-day or less turnaround. 
Stratiﬁcation factors are: number of positive (1 vs. 2) EGFR tests, 
performance status (0/1 vs. 2), extent of disease (stage IIIB vs. IV), and 
cigarette smoking status (current vs. former vs. never). The primary 
study endpoint is disease progression at 6 months. Secondary endpoints 
include PFS, OS, and response rate. Enrollment goal is 140 pts.
Results: As of February 19, 2007, 66 pts have been randomized (33 E; 
33 ECP). Median age is 61 yrs (range, 31-87); 61% are female; 12% 
Asian; 36% never smokers, 12% current smokers, and 52% former 
smokers; 94% ECOG PS 0/1; 89% Stage IV; 77% adenocarcinoma. 
Median EGFR reporting time is 4 days (range, 1-9). 88% of random-
ized pts’ tumors are IHC positive, 53% FISH positive, and 41% 
are both IHC and FISH positive for EGFR. 123 patients have been 
screened: 8% of pts’ tumors are EGFR IHC and FISH negative and 
15% are not sufﬁcient for EGFR testing. Of randomized patients, 12% 
have EGFR mutations and 11% have KRAS mutations. There are no 
notable differences in demographics or baseline characteristics between 
arms with the exception of more females and PS 0 patients in the E 
arm. Preliminary safety data show no notable differences between treat-
ment arms.
Conclusions: Selection of untreated advanced NSCLC pts for E 
therapy based on real-time EGFR testing of tumor tissue is feasible. 
Preliminary evaluation of efﬁcacy and safety data will be presented.
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tumour biomarkers and clinical benefit from erlotinib in advanced 
non-small cell lung cancer (NSCLC)
Tan, Eng-Huat1 Ramlau, Rodryg2 Pluzanska, Anna3 Kuo, Han-Pin4 
Klughammer, Barbara5 Kockx, Mark6 Carreras, Maximo7 Lutz, Verena8 
Essioux, Laurent7 Baselga, Jose9 
1 National Cancer Centre, Singapore, 2 Regional Lung Disease Centre, 
Poznan, Poland 3 Regional Oncology Centre, Lodz, Poland 4 Chang 
Gung Memorial Hospital, Linkou, Taiwan 5 F. Hoffmann-La Roche Ltd, 
Basel, Switzerland 6 HistoGeneX, Antwerp, Belgium 7 F. Hoffmann La-
Roche Ltd, Basel, Switzerland 8 Roche Diagnostics GmbH, Penzberg, 
Germany 9 Vall d’Hebron University Hospital, Barcelona, Spain 
Background: Erlotinib (Tarceva®), a potent, orally active inhibitor of 
EGFR tyrosine kinase, signiﬁcantly prolonged survival, delayed symp-
tom progression and improved quality of life compared with placebo in 
patients with relapsed NSCLC (Shepherd et al. NEJM 2005;353:123-
132). Exploratory univariate analyses suggested a beneﬁcial effect of 
erlotinib on survival in patients with EGFR-positive tumours or high 
EGFR gene copy number (Tsao et al. NEJM;353:133-144). In a mul-
tivariate analysis, survival on erlotinib was not signiﬁcantly affected 
by EGFR expression status, EGFR copy number, or EGFR mutation 
status, but relationships between such markers and clinical outcomes on 
erlotinib have not been prospectively evaluated. The goal of the multi-
centre, open-label phase II MERIT study was to identify molecular 
markers that may be predictive for clinical beneﬁt with erlotinib. 
Methods: Eligible patients had advanced (stage IIIB/IV) NSCLC, 
ECOG PS 0-2, were ≥ 18 years old, and had failed ≥ one chemotherapy 
regimen (or refused/were unsuitable for chemotherapy). An important 
inclusion criterion was that a tumour biopsy should be performed by 
bronchoscopy prior to the start of treatment. Erlotinib (150mg/day p.o.) 
was given until disease progression, death, or unacceptable toxicity. 
Dose reductions were permitted for adverse events (AEs). Tumour re-
sponse was assessed every 6 weeks until week 24, then every 12 weeks. 
Clinical beneﬁt was deﬁned as either an objective response (RECIST), 
or stable disease ≥ 12 weeks. Safety assessments (laboratory tests and 
AE recording) were performed at regular intervals. Tumour biopsies 
were analysed using gene expression proﬁling on fresh-frozen tissue, 
and IHC for EGFR and downstream signalling molecules. Receptor 
mutations were evaluated by DNA sequencing, and gene ampliﬁcation 
was assessed using FISH. 
Results: 264 patients from 26 centres in 12 countries were available 
for evaluation of efﬁcacy. Their median age was 61.0 years (range 
32–85). Other baseline characteristics were: male, 70%; female 30%; 
stage IIIB, 26%; stage IV, 74%; ECOG PS 0, 13%; PS 1, 64%; PS 2, 
23%; Caucasian, 61%; Oriental, 38%; other, <1%; non-smoker, 27%; 
ever-smoker, 73% (current, 27%; past, 46%); adenocarcinoma, 41%; 
squamous-cell carcinoma, 38%; large-cell carcinoma, 5%; other, 17%. 
236 patients (89.4%) had previously received chemotherapy (includ-
ing neo-adjuvant and adjuvant treatment). For most patients in MERIT 
(130; 49.2%) erlotinib was second-line therapy, but 72 (27.3%) re-
ceived third-line and 62 (23.5%) ﬁrst-line erlotinib. 36 patients (13.6%) 
had an objective response; 83 (31.4%) had clinical beneﬁt. Median 
overall survival was 7.6 months (95% CI 7-9); median progression-free 
survival was 11.3 weeks (95% CI 8-12). 226 of 257 patients (87.9%) 
had at least one AE, and 62 (24.1%) had a serious AE. 193 patients 
(75.1%) had at least one treatment-related AE and 37.4% had at least 
one AE ≥ grade (gr) 3. The most common AEs were: rash (61.9%; 
